Current Report · Items 1.02 · 8-K

Medicinova Inc

MNOVNASDAQEQUITYCurrent

Termination of a Material Definitive Agreement

Item 1.02 Termination of a Material Definitive Agreement. Termination of Standby Equity Purchase Agreement On August 31, 2026, MediciNova, Inc. (the “Company”) delivered to YA II PN, LTD.…

Filed Sep 2, 2026Accepted Sep 2, 2026, 7:30 AM EDTCIK 1226616Accession 0001193125-26-379348

View company →Permanent SEC source ↗

Company context

We are a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (“U.S.”) market. Our current strategy is to focus our development activities on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (“MS”), amyotrophic lateral sclerosis (“ALS”), chemotherapy-induced peripheral neuropathy (“CIPN”), degenerative cervical myelopathy (“DCM”), glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence), and prevention of acute respiratory distress syndrome (“ARDS”), and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (“NAFLD”), and hypertriglycedemia.

Current securities

MNOVNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 1.02

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.02Item 1.02 - Termination of Material Agreement

Item 1.02 Termination of a Material Definitive Agreement. Termination of Standby Equity Purchase Agreement On August 31, 2026, MediciNova, Inc. (the “Company”) delivered to YA II PN, LTD. (“Yorkville”), a Notice of Termination, informing Yorkville of the Company’s election to terminate the Standby Equity Purchase Agreement, dated as of July 30, 2025, by and between the Company and Yorkville (the “SEPA”), as required under Section 9.01(b) of the SEPA. Termination of the SEPA will become effective as of September 8, 2026. As previously disclosed in the Current Report on Form 8-K filed by the Company on August 1, 2025, pursuant to the SEPA, and upon the terms and subject to the conditions therein, the Company had the right, but not the obligation, to issue and sell to Yorkville up to $30.0 million of its shares of common stock. The Company sold an aggregate of 175,000 shares of its common stock at prices ranging from $1.39 to $1.40 per share for aggregate proceeds of $0.2 million under the SEPA. At the time of the termination, there were no outstanding borrowings, advance notices or shares of common stock to be issued, under the SEPA. In addition, there are no fees due by the Company or Yorkville in connection with the termination of the SEPA.

Free Registration